Distinguished in Hemorrhagic Proctocolitis

Shintaro Sagami

Tokyo, JP 
Distinguished in Hemorrhagic Proctocolitis
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Shintaro Sagami practices in Tokyo, Japan. Mr. Sagami is rated as a Distinguished expert by MediFind in the treatment of Hemorrhagic Proctocolitis. His top areas of expertise are Colitis, Ulcerative Colitis, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 23 articles and participated in 3 clinical trials in the study of Hemorrhagic Proctocolitis.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Minato, Japan
Kitamoto, Japan
Hiroshima, Japan
Onomichi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

46 Total Publications

Early Reduction in Rectal Wall Thickness on Transperineal Ultrasound Predicts Mucosal Healing in Ulcerative Colitis.
Early Reduction in Rectal Wall Thickness on Transperineal Ultrasound Predicts Mucosal Healing in Ulcerative Colitis.
Journal: Journal of Crohn's & colitis
Published: August 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sagami's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile